FASLG and urinary bladder cancer: Even if the three different rising ATRA concentrations were analyzed from nutraceutical to pharmacological ones, up to the toxic one, the 10 μM concentration was used in the subsequent analyses to perform comparison with the existing literature on bladder cancer, and to maintain a range similar to APL pharmacological treatment [15].